• 1. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 2. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 3. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 4. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 5. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020

Introduction to 4-Amino-1,3-Dimethyl-1H-Pyrazole-5-Carbonitrile (CAS No. 32183-14-5)

4-Amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile (CAS No. 32183-14-5) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique molecular structure, exhibits a range of biological activities that make it a valuable candidate for various therapeutic applications. In this comprehensive introduction, we will delve into the chemical properties, synthesis methods, biological activities, and potential applications of 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile.

The molecular formula of 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile is C₇H₉N₄, and its molecular weight is approximately 147.17 g/mol. The compound features a pyrazole ring with an amino group at the 4-position and methyl groups at the 1 and 3 positions, along with a cyano group at the 5-position. This specific arrangement of functional groups imparts unique chemical and biological properties to the molecule.

In terms of chemical synthesis, 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile can be synthesized through various routes. One common method involves the reaction of 1,3-dimethylpyrazole with an appropriate nitrile derivative in the presence of a suitable catalyst. Recent advancements in green chemistry have led to the development of more environmentally friendly synthesis methods, such as using microwave-assisted reactions or employing catalysts derived from renewable sources.

The biological activities of 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile have been extensively studied in recent years. One of the most notable properties is its potential as an inhibitor of specific enzymes involved in various disease pathways. For instance, research has shown that this compound can inhibit the activity of certain kinases, which are key targets in cancer therapy. Additionally, studies have demonstrated that 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile possesses anti-inflammatory and analgesic properties, making it a promising candidate for the treatment of inflammatory diseases and pain management.

In the context of medicinal chemistry, 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile has been explored as a lead compound for drug development. Its ability to modulate specific biological targets has led to its evaluation in preclinical studies for various therapeutic indications. For example, it has shown promise in reducing tumor growth in animal models of cancer and has demonstrated efficacy in alleviating symptoms in models of inflammatory diseases.

The pharmacokinetic properties of 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile are also an important consideration for its potential use as a therapeutic agent. Studies have indicated that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. Its oral bioavailability is relatively high, and it has been shown to have good stability under physiological conditions. These properties make it an attractive candidate for further development into a viable drug product.

In addition to its therapeutic potential, 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile has also been investigated for its use as a building block in the synthesis of more complex molecules. Its versatile reactivity allows it to be readily modified through various chemical transformations, enabling the creation of structurally diverse derivatives with enhanced biological activities or improved pharmacological profiles.

The safety profile of 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile is another critical aspect that has been evaluated in preclinical studies. Toxicity assessments have shown that this compound is generally well-tolerated at therapeutic doses and does not exhibit significant adverse effects on major organ systems. However, as with any new chemical entity (NCE), ongoing safety monitoring is essential to ensure its safe use in clinical settings.

In conclusion, 4-amino-1,3-dimethyl-1H-pyrazole-5-carbonitrile (CAS No. 32183-14-5) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and favorable biological properties make it an attractive candidate for further development into therapeutic agents for various diseases. Ongoing research continues to uncover new insights into its mechanisms of action and potential clinical uses, highlighting its significance in the field.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)